Sung‐Bae Kim

1988–2026 年に発表

別表記
Sung Bae Kim · Sung-Bae Kim · Sung-bae Kim
204
論文数
41,740
被引用数
80
h 指数
180
i10 指数

被引用数

Sung‐Bae Kim の年別被引用数1971 年: 被引用 1 件1990 年: 被引用 3 件1991 年: 被引用 2 件1992 年: 被引用 3 件1993 年: 被引用 9 件1994 年: 被引用 7 件1995 年: 被引用 5 件1996 年: 被引用 2 件1997 年: 被引用 8 件1998 年: 被引用 2 件1999 年: 被引用 6 件2000 年: 被引用 1 件2001 年: 被引用 7 件2002 年: 被引用 5 件2003 年: 被引用 4 件2004 年: 被引用 10 件2005 年: 被引用 10 件2006 年: 被引用 4 件2007 年: 被引用 18 件2008 年: 被引用 25 件2009 年: 被引用 30 件2010 年: 被引用 37 件2011 年: 被引用 32 件2012 年: 被引用 76 件2013 年: 被引用 116 件2014 年: 被引用 131 件2015 年: 被引用 173 件2016 年: 被引用 216 件2017 年: 被引用 220 件2018 年: 被引用 242 件2019 年: 被引用 1,017 件2020 年: 被引用 1,495 件2021 年: 被引用 1,743 件2022 年: 被引用 2,020 件2023 年: 被引用 1,780 件2024 年: 被引用 2,921 件2025 年: 被引用 1,518 件2026 年: 被引用 33 件1972〜1989 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,512 件、この内訳の 20.7%中国: 引用元論文 2,185 件、この内訳の 12.9%イタリア: 引用元論文 1,119 件、この内訳の 6.6%日本: 引用元論文 798 件、この内訳の 4.7%イギリス: 引用元論文 796 件、この内訳の 4.7%ドイツ: 引用元論文 773 件、この内訳の 4.6%フランス: 引用元論文 733 件、この内訳の 4.3%スペイン: 引用元論文 683 件、この内訳の 4%韓国: 引用元論文 501 件、この内訳の 3%カナダ: 引用元論文 481 件、この内訳の 2.8%スイス: 引用元論文 423 件、この内訳の 2.5%オーストラリア: 引用元論文 407 件、この内訳の 2.4%
0%20.7%その他 26.8%

分野

  • Medicine69.6%
  • Biochemistry, Genetics and Molecular Biology19.9%
  • Immunology and Microbiology2.5%
  • Materials Science2.4%
  • Engineering1.9%
  • Computer Science1.1%
  • その他2.6%

トピック

  • HER2/EGFR in Cancer Research9.2%
  • Cancer Immunotherapy and Biomarkers6.6%
  • Breast Cancer Treatment Studies5.4%
  • Advanced Breast Cancer Therapies4.7%
  • Monoclonal and Polyclonal Antibodies Research3.6%
  • Cancer Treatment and Pharmacology2.8%
  • その他67.7%

共著者

全論文

検索で開く
  1. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron - New England Journal of Medicine 2022 被引用: 2,548

  2. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 1,973

  3. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 被引用: 1,124

  4. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2021 被引用: 1,580

  5. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2022 被引用: 642

  6. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joseph A. Sparano, Tanja Španić, Sandra M. Swain, Sergei Tjulandin, Masakazu Toi, Dario Trapani, Andrew Tutt, B. Xu, Giuseppe Curigliano, Nadia Harbeck - Annals of Oncology 2023 被引用: 844

  7. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesco Caponigro, Ana Castro, Terrence P. Cescon, Kelvin Chan, Arvind Chaudhry, Bruno Chauffert, Ezra E.W. Cohen, Tibor Csőszi, Jan Paul de Boer, Jean‐Pierre Delord, Andreas Dietz, José Dinis, Charlotte Dupuis, Laurence Digue, József Erfán, Yolanda Escobar Alvarez, Mererid Evans, Mary J. Fidler, Martin Förster, Signe Friesland, Apar Kishor Ganti, Lionnel Geoffrois, Clíona Grant, Viktor Gruenwald, Kevin J. Harrington, Thomas K. Hoffmann, Geza Horvai, Arturas Inčiūra, Raymond Woo-Jun Jang, Petra Jankowska, Antonio Jimeno, Mano Joseph, Alejandro Juárez Ramiro, Bogusława Karaszewska, Andrzej Kawecki, Ulrich Keilholz, Ulrich Keller, Sung‐Bae Kim, Judit Kocsis, Nuria Kotecki, Mark Kozloff, J. Lambea, László Landherr, Yuri Lantsukhay, Sergey Lazarev, Lip Way Lee, Christophe Le Tourneau, Lisa Licitra, Igor Lifirenko, Nicolas Mach, Danko Martincic, О. В. Маторин, Margaret McGrath, Jean‐Pascal Machiels, Ranee Mehra, Krzysztof Misiukiewicz, John C. Morris, Ф. Ф. Муфазалов, Jiaxin Niu, Devraj Srinivasan, Pedro Pérez Segura, Daniel Rauch, Maria Leonor Ribeiro, Cristina P. Rodriguez, Frédéric Rolland, Antonio Russo, Ágnes Ruzsa, Frederico Sanches, Sangwon Shin, Mikhail Shtiveland ほか 13 名 - The Lancet 2018 被引用: 1,697

  8. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 1,887

  9. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 1,176

  10. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2023 被引用: 345

  11. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maria Alejandra Bartoli, Norberto Batista López, María Inés Bianconi, Laura Biganzoli, Ruemu Birhiray, Marianna Bitiņa, Ron Blachy, Kimberly Blackwell, Rita A. Blanchard, Paulette Blanchet, Ion Boiangiu, B. Bower, Christine Brezden‐Masley, Adam Brufsky, Leanne S. Budde, Priscilla B. Caguioa, Lourdes Calvo, Mario Campone, Robert R. Carroll, Hugo R. Castro, Valorie F. Chan, Veena Charu, Saverio Cinieri, Michael Clemens, Emilio Alba Conejo, Eduardo Côrtes, Bruno Coudert, Eduardo Cronemberger, Daniel de Iracema Gomes Cubero, Shaker R. Dakhil, Brooke Daniel, Neville Davidson, Maria de Fátima Dias Gauí, Susana de la Cruz, María del Pilar, G. Delgado, John Ellerton, César Estuardo, Louis Fehrenbacher, Jean-­Marc Ferrero, Patrick J. Flynn, Małgorzata Foszczyńska‐Kłoda, Sandra Franco, Hirofumi Fujii, Chris Gallagher, Teresa Gamucci, N Giacomi, Miguel Gil Gil, Antonio González-Martı́n, Vera Gorbunova, E. Gotovkin, Nathan Green, Elza Grincuka, Eva‐Maria Grischke, Vincent Hansen, Jeffrey B. Hargis, Maik Hauschild, Roberto Hegg, Carolyn B. Hendricks, Róbert Hermann, Paulo M. Hoff, Jun Horiguchi, Javier Hornedo Muguiro, Stefano Iacobelli, Kenichi Inoue, Gustavo Ismael, Yoshinori Itoh, Dr Hiroji Iwata, D Jendiroba, Rosa Jochim ほか 122 名 - The Lancet Oncology 2020 被引用: 898

  12. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 2,071

  13. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

    著者: , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 2,139

  14. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2019 被引用: 1,231

  15. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

    著者: , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 375

  16. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

    著者: , , , , , , , , , , , , , - New England Journal of Medicine 2011 被引用: 2,523

  17. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bin Yao, Judith D. Bebchuk, Kiana Keyvanjah, Richard Bryce, Adam Brufsky, for the NALA Investigators - Journal of Clinical Oncology 2020 被引用: 609

  18. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , for the RATIONALE-302 Investigators - Journal of Clinical Oncology 2022 被引用: 306

  19. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Jing Huang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean‐Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang ほか 33 名 - The Lancet Oncology 2023 被引用: 200

  20. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 324

  21. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    著者: , , , , , , , , - The Lancet Oncology 2017 被引用: 523

  22. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , SOPHIA Study Group - JAMA Oncology 2021 被引用: 349

  23. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sabine C. Linn, Matthew P. Goetz, Stefan Michiels, International Immuno-Oncology Biomarker Working Group - JAMA 2024 被引用: 199

  24. Tipifarnib in Head and Neck Squamous Cell Carcinoma WithHRASMutations

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 196